Outline
MEDICATIONS
There is some debate as to whether treatment of fever is beneficial.
- Beneficial effects of fever include enhancement of host defenses and inhibition of certain neoplastic cells. Several animal studies looking at serious infection have shown an inverse correlation between mortality and temperature
- Detrimental effects of fever include muscle atrophy and weakness due to increased catabolism, increased metabolic rate, anorexia, seizures (>108°F, 42°C) and prolonged fever can result in cardiovascular collapse
- Reducing fever is often thought to improve patient comfort, but it is difficult to discern if this effect is due to reducing fever or secondary to the analgesic effects of most antipyretic medications
- External cooling has been shown in humans to increase discomfort. This should be considered prior to administering alcohol baths
Drug(s) of Choice
NSAIDs
Weigh benefits, disadvantages, and potential side effects.
Corticosteroids
- Anti-inflammatory agents, and at higher doses immunosuppressive agents (dexamethasone, prednisolone, and prednisolone sodium succinate). These drugs can be useful in the treatment of selected nonseptic inflammatory and immune-mediated diseases. Occasionally used as a powerful anti-inflammatory in the presence of infections (R. equi pneumonia and acute respiratory distress syndrome)
- Other anti-inflammatory drugs that are in use include azathioprine, cyclophosphamide, aurothioglucose, and pentoxifylline
Antimicrobials
- Ideally, the source of fever and etiologic agent should be identified before antimicrobial therapy is initiated. Bacterial sources of fever should be treated with antibiotics based on culture and sensitivity results. The location of infection must be taken into consideration with appropriate antimicrobials chosen to target this location. In circumstances where empirical treatment must be initiated without the benefit of culture and sensitivity results, broad-spectrum antimicrobial cover should be initiated
- Local therapy may be more appropriate than systemic therapy (i.e. intra-articular and regional administration in septic joints/osteomyelitis)
- Fungal disease can be difficult to treat in the horse due to the lack of availability of antifungal agents and the expense of treatment. Therapy should ideally be initiated based on culture and sensitivity results
- Parasitism should be treated with institution of a comprehensive deworming program based on the needs and facilities of the individual horse and property. It is important to monitor for development of resistance and to treat for encysted cyathostomes and tapeworms
- Viral disease rarely has directed therapeutic options and care normally involves supportive therapy. Acyclovir (aciclovir) has been used in treatment of the neurologic form of EHV-1, and interferon therapy has been tried in the treatment of WNV
Precautions
NSAIDs
Can result in nephrotoxicity, right dorsal colitis, gastric ulceration. Side effects are more common in dehydrated or hypovolemic animals, and when administered concurrently with other nephrotoxic agents such as aminoglycosides, tetracyclines, and amphotericin B.
Corticosteroids
- Can induce hypothalamicpituitaryadrenal system suppression or immunosuppression
- Have been associated with development, or worsening, of laminitis
Antimicrobials
- Can result in antibiotic-induced colitis. Aminoglycosides, oxytetracycline, and amphotericin B are potentially nephrotoxic. Aminoglycoside therapeutic drug monitoring is recommended
- Itraconazoleuse with care in cases with hepatic impairment
Possible Interactions
- Care should be taken in using multiple drugs that are potentially nephrotoxic in patients that are dehydrated or hypovolemic
- α2-Agonist drugs (e.g. xylazine, detomidine) may induce tachypnea and nostril flaring in horses with pyrexia
Dinarello CA. Infection, fever, and exogenous and endogenous pyrogens: some concepts have changed. J Endotoxin Res 2004;10:201222.
Greisman LA, Mackowiak PA. Fever: beneficial and detrimental effects of antipyretics. Curr Opin Infect Dis 2002;15:241245.
Author: Michelle Abraham Linton
Consulting Editor: Ashley G. Boyle
Acknowledgment: The author and editor acknowledge the prior contribution of Julie Ross.